Review
Rheumatology
Alexandre Sepriano, Andreas Kerschbaumer, Sytske Anne Bergstra, Josef S. Smolen, Desiree van der Heijde, Roberto Caporali, Christopher J. Edwards, Patrick Verschueren, Savia de Souza, Janet Pope, Tsutomu Takeuchi, Kimme Hyrich, Kevin L. Winthrop, Daniel Aletaha, Tanja Stamm, Jan W. Schoones, Robert B. M. Landewe
Summary: This study conducted a systematic literature review (SLR) to evaluate the safety of synthetic and biological disease-modifying antirheumatic drugs (DMARDs) for the management of rheumatoid arthritis (RA). The results indicated that bDMARDs were associated with an increased risk of serious infections compared to csDMARDs, while JAK inhibitors (JAKi) showed higher risk of herpes zoster infections. The risks of malignancies, major adverse cardiovascular events (MACE), and venous thromboembolism (VTE) were similar among different treatments.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Medicine, General & Internal
Mattia Bellan, Lorenza Scotti, Daniela Ferrante, Elisa Calzaducca, Giulia Francesca Manfredi, Pier Paolo Sainaghi, Francesco Barone-Adesi
Summary: This study compares the risk of severe infections among different classes of biological disease-modifying anti-rheumatic drugs (bDMARDs) using administrative data. The results show that the use of Tocilizumab is associated with an increased risk of infection compared to tumor necrosis factor (TNF) inhibitor drugs, while no difference in the risk of severe infection was found for abatacept. This suggests that there are slight but important differences in the safety of different classes of bDMARDs in clinical practice.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Layth Ben-Trad, Constantin Ionut Matei, Mirela Maria Sava, Samira Filali, Marie-Eve Duclos, Yves Berthier, Michel Guichardant, Nathalie Bernoud-Hubac, Ofelia Maniti, Ahmed Landoulsi, Marie-Genevieve Blanchin, Pierre Miossec, Thierry Granjon, Ana-Maria Trunfio-Sfarghiu
Summary: This study compares the biochemical, tribological, and ultrastructural properties of synovial fluid in healthy individuals and patients with osteoarthritis and arthritis, finding differences that indicate the importance of synovial fluid in joint mechanics.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Maria Sofia Ciliento, Veronica Venturelli, Natale Schettini, Riccardo Bertola, Carlo Garaffoni, Giovanni Lanza, Roberta Gafa, Alessandro Borghi, Monica Corazza, Alen Zabotti, Sonia Missiroli, Caterina Boncompagni, Simone Patergnani, Mariasole Perrone, Carlotta Giorgi, Paolo Pinton, Marcello Govoni, Carlo Alberto Scire, Alessandra Bortoluzzi, Ettore Silvagni
Summary: The aim of this systematic literature review was to investigate the effects of b/tsDMARDs on the synovial membrane of PsA patients and identify biomarkers of response to therapy. A meta-analysis of 22 studies showed a significant reduction in CD3+ lymphocytes and CD68+ macrophages in synovial biopsies from patients treated with bDMARDs for 4-12 weeks. Reduction in CD3+ was correlated with clinical response. The most consistent finding in the literature was the reduction in CD3+/CD68+ sublining cells during the first 3 months of treatment with TNF inhibitors.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, General & Internal
Vandana Bhushan, Susan Lester, Liz Briggs, Raif Hijjawi, E. Michael Shanahan, Eliza Pontifex, Jem Ninan, Catherine Hill, Fin Cai, Jennifer Walker, Fiona Goldblatt, Mihir D. Wechalekar
Summary: Similar retention rates of the second and third compared to the first b/tsDMARD in RA, PsA, and AS support a differential b/tsDMARDs use strategy based on patient presentation. The risk of b/tsDMARD failure was halved in PsA patients, and covariates were not associated with the risk of bDMARD failure. The most common reason for switching was treatment failure.
FRONTIERS IN MEDICINE
(2021)
Review
Rheumatology
Andreas Kerschbaumer, Alexandre Sepriano, Sytske Anne Bergstra, Josef S. Smolen, Desiree van der Heijde, Roberto Caporali, Christopher John Edwards, Patrick Verschueren, Savia de Souza, Janet E. Pope, Tsutomu Takeuchi, Kimme L. Hyrich, Kevin L. Winthrop, Daniel Aletaha, Tanja A. Stamm, Jan W. Schoones, Robert B. M. Landewe
Summary: This study aimed to update the evidence on the efficacy of DMARDs and provide information for the 2022 update of EULAR recommendations for RA management. A systematic literature review was conducted to investigate the efficacy of cs, b, biosimilar, and tsDMARDs in RA patients. The results showed that csDMARDs combined with short-term glucocorticoids in early RA were as effective as bDMARD+MTX combination therapy. JAK inhibitors were effective in different patient populations. Tapering of DMARDs was feasible for some patients who could maintain low disease activity or achieve remission.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Health Care Sciences & Services
Hanna Gul, Kate Harnden, Benazir Saleem
Summary: It has been demonstrated that drug-free remission (DFR) is possible in a proportion of rheumatoid arthritis (RA) patients achieving clinically defined remission. Immunological, imaging, and clinical associations with/predictors of DFR have been identified. This has implications for reducing medication-induced side effects, treatment burden, and cost effectiveness, particularly for biologic therapy.
Article
Biochemistry & Molecular Biology
Chiara Baggio, Roberto Luisetto, Carlotta Boscaro, Anna Scanu, Roberta Ramonda, Mattia Albiero, Paolo Sfriso, Francesca Oliviero
Summary: Genomic damage is associated with autoimmune processes, chronic inflammation, and apoptosis. The T cell compartment may exhibit overall genomic instability in certain rheumatological diseases. However, there is limited knowledge regarding leukocyte abnormalities in synovial fluid (SF) and their connection to inflammation. This study aimed to investigate cellular phenotypes in SF from patients with various inflammatory arthropathies. The results showed that inflammatory SF is associated with genomic instability and abnormal cell subsets.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Rheumatology
Daniel Maunder, Philip M. Brown, Ben Barron-Millar, Dennis W. Lendrem, Najib Naamane, Jamie Macdonald, Xiao N. Wang, John D. Isaacs, Amy E. Anderson, Ann W. Morgan, Rachel E. Crossland, Sarah L. Mackie, Arthur G. Pratt
Summary: This study evaluated the potential of serum EV miRs as diagnostic and therapeutic biomarkers in early RA and found a novel potential mechanism by which MTX may exert its therapeutic effect in early RA.
Review
Biochemistry & Molecular Biology
Susan Siyu Wang, Myles J. Lewis, Costantino Pitzalis
Summary: Rheumatoid arthritis (RA) is a complex disease with heterogeneity in disease severity and treatment response. Current prediction methods for treatment response have limitations, and genetics and environmental factors alone cannot fully explain the differences between patients. Recent studies have shown that DNA methylation plays a role in the pathogenesis and progression of RA, and specific DNA methylation profiles in the blood may serve as predictive biomarkers. This review examines the evidence for DNA methylation signatures in treatment response and discusses the potential for future progress in this area.
Review
Medicine, General & Internal
Mengduan Pang, Zhe Sun, Hongfeng Zhang
Summary: This meta-analysis compared the risk of all-cause mortality between biological/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) and non-b/tsDMARDs in patients with rheumatoid arthritis (RA). The results showed that compared to non-b/tsDMARDs, antitumor necrosis factor therapy was associated with an increased risk of mortality.
Article
Biotechnology & Applied Microbiology
Sajeev Kumar Babasahib, Roaddy Well Born, Nulgumnalli Manjunathaiah Raghavendra
Summary: In this study, the authors developed NAP and SULF ethosomes in hydrogel carrier, which showed stable and effective anti-inflammatory effects in vivo. The NAP-SULF ethosomes-hydrogel demonstrated sustained drug release and significant inhibition of inflammation, potentially serving as a novel approach for the treatment of RA.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY
(2022)
Article
Immunology
Zahra Mahmoudi, Negin Karamali, Seyed Askar Roghani, Shirin Assar, Mehran Pournazari, Parviz Soufivand, Farhad Salari, Alireza Rezaiemanesh
Summary: The study investigated the gene expression levels of MALAT1, H19, miR-199a-5p, and miR-1-3p in RA patients. MALAT1 and H19 may serve as potential biomarkers for distinguishing RA patients from controls.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Multidisciplinary Sciences
Bin Zhao, Lingting Zeng, Danyang Chen, Songqing Xie, Zhaokui Jin, Guanglin Li, Wei Tang, Qianjun He
Summary: This study proposes a concept of photocatalytic regulation of the synovial microenvironment (SME) for arthritis treatment. Monodispersive hydrogen-doped titanium dioxide nanorods with a rutile single-crystal structure are developed to achieve near infrared-photocatalytic generation of hydrogen molecules and depletion of lactic acid (LA) in a collagen-induced mouse model of rheumatoid arthritis. The results show that locally produced hydrogen molecules scavenge reactive oxygen species and regulate the synovial microenvironment, thereby preventing synovial pannus formation and cartilage destruction.
Article
Biochemistry & Molecular Biology
Andrew D. Foers, Alexandra L. Garnham, Simon Chatfield, Gordon K. Smyth, Lesley Cheng, Andrew F. Hill, Ian P. Wicks, Ken C. Pang
Summary: In rheumatoid arthritis, extracellular vesicles are associated with joint inflammation and destruction. Through sequencing EV miRNAs in synovial fluid from RA patients, differences between joints with high- and low-grade inflammation were identified, suggesting a role in regulating inflammation-related genes. EV miRNAs have the potential to modulate inflammation and contribute to RA pathophysiology.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
